11:46 AM EDT, 10/28/2025 (MT Newswires) -- DexCom ( DXCM ) shares were down over 2% in recent Tuesday trading after Hunterbrook issued a report about multiple deaths allegedly related to the company's G7 continuous glucose monitor.

The report said that three people with diabetes have died after using the monitor, according to adverse event reports filed with the US Food and Drug Administration in September.

A recent investigation by Hunterbrook found that Dexcom ( DXCM ) "dropped the ball," as some patients relying on the device ended up hospitalized or dead. After the investigation was published last month, two law firms filed class-action lawsuits claiming the devices were not as accurate as advertised. A securities lawsuit was also filed on Monday, the report said, adding that Hunterbrook Capital is short DexCom ( DXCM ) at the time of publication.

Since its launch in 2023 at least 13 G7 users have died, Hunterbrook said citing the FDA's Manufacturer and User Facility Device Experience reports. The regulator sent Dexcom ( DXCM ) a warning letter in March, the report said.

Dexcom ( DXCM ) is set to release its Q3 financial results after market close on Thursday.

The company didn't immediately reply to MT Newswires' request for comment.

Price: 69.07, Change: -1.56, Percent Change: -2.21